Status: Recruiting
A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
Participants needed: 42
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Boston PharmaceuticalsUpdated: Dec 24, 2025Locations: 35
Eligibility criteria
Ability to understand and sign a written informed consent form (ICF) [+4]
Individuals with chronic liver disease from other causes, or any history or evid... [+3]